T0901317 - ≥98%, high purity , CAS No.293754-55-9, Agonist of Liver X receptor-α;Agonist of Liver X receptor-β;Agonist of RAR-related orphan receptor-α;Agonist of RAR-related orphan receptor-γ

Item Number
T129709
Grouped product items
SKUSizeAvailabilityPrice Qty
T129709-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$29.90
T129709-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
T129709-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$75.90
T129709-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$95.90
T129709-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$149.90

Potent, non-selective LXR agonist

Basic Description

SynonymsT-0901317 | T 0901317 | N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsT 0901317 is a cell-permeable, nonsterol, benzenesulfonamide compound that acts as a highly selective and potent liver X receptor (LXR) agonist (EC50 of 20 nM for LXRα). T 0901317 is reported to induce the expression of genes associated with fatty acid bi
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of Liver X receptor-α;Agonist of Liver X receptor-β;Agonist of RAR-related orphan receptor-α;Agonist of RAR-related orphan receptor-γ
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively.
A cell-permeable, nonsterol compound that acts as a highly potent LXR activator

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide
INCHI InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2
InChi Key SGIWFELWJPNFDH-UHFFFAOYSA-N
Canonical SMILES C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
Isomeric SMILES C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
Alternate CAS 293754-55-9
PubChem CID 447912
MeSH Entry Terms N-(2,2,2-Trifluoroethyl)-N-(4-(2,2,2-trifluoro-1- hydroxy-1-trifluoromethylethyl)phenyl)benzenesulfonamide;N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2
Molecular Weight 481.33

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot NumberCertificate TypeDateItem
C2404048Certificate of AnalysisFeb 21, 2024 T129709
C2404053Certificate of AnalysisFeb 21, 2024 T129709
C2404054Certificate of AnalysisFeb 21, 2024 T129709
C2404057Certificate of AnalysisFeb 21, 2024 T129709
C2404059Certificate of AnalysisFeb 21, 2024 T129709
C2404060Certificate of AnalysisFeb 21, 2024 T129709
C2404066Certificate of AnalysisFeb 21, 2024 T129709
C2404067Certificate of AnalysisFeb 21, 2024 T129709
C2404069Certificate of AnalysisFeb 21, 2024 T129709
E1716084Certificate of AnalysisJan 14, 2023 T129709

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Yan Zhu, Yanni Xu, Dong Han, Xiujin Zhang, Cheng Qin, Jing Liu, Lei Tian, Mengqi Xu, Yan Fang, Yang Zhang, Yabin Wang, Feng Cao.  (2023)  Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation.  Nanomedicine-Nanotechnology Biology and Medicine,  50  (102672).  [PMID:37044196] [10.1016/j.nano.2023.102672]
2. Yanyan Wang, Hai Gao, Xinya Huang, Zhaoan Chen, Pengyu Kang, Yunyi Zhou, Danhua Qin, Wenli Zhang, Jianping Liu.  (2022)  Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis.  CARBOHYDRATE POLYMERS,  292  (119632).  [PMID:35725197] [10.1016/j.carbpol.2022.119632]

References

1. Han S, Zhuang H, Shumyak S, Wu J, Xie C, Li H, Yang LJ, Reeves WH.  (2018)  Liver X Receptor Agonist Therapy Prevents Diffuse Alveolar Hemorrhage in Murine Lupus by Repolarizing Macrophages..  Front Immunol,  (13): (135).  [PMID:29456535] [10.1021/op500134e]
2. Wang J, Xiao C, Wei Z, Wang Y, Zhang X, Fu Y.  (2018)  Activation of liver X receptors inhibit LPS-induced inflammatory response in primary bovine mammary epithelial cells..  Vet Immunol Immunopathol,  197  (13): (87-92).  [PMID:29475512] [10.1021/op500134e]
3. Zhang CJ et al..  (2021)  Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma..  Acta Pharmacol Sin,  42  (9): (1472-1485).  [PMID:33303989]
4. Wu D et al..  (2021)  Dichlorodiphenyltrichloroethane Impairs Amyloid Beta Clearance by Decreasing Liver X Receptor a Expression..  Front Aging Neurosci,  13  (634948).  [PMID:34045954]
5. Yan Zhu, Yanni Xu, Dong Han, Xiujin Zhang, Cheng Qin, Jing Liu, Lei Tian, Mengqi Xu, Yan Fang, Yang Zhang, Yabin Wang, Feng Cao.  (2023)  Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation.  Nanomedicine-Nanotechnology Biology and Medicine,  50  (102672).  [PMID:37044196] [10.1016/j.nano.2023.102672]
6. Yanyan Wang, Hai Gao, Xinya Huang, Zhaoan Chen, Pengyu Kang, Yunyi Zhou, Danhua Qin, Wenli Zhang, Jianping Liu.  (2022)  Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis.  CARBOHYDRATE POLYMERS,  292  (119632).  [PMID:35725197] [10.1016/j.carbpol.2022.119632]

Solution Calculators